Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues

Physiological Genomics

Volumn 31, Issue 1, 2007, Pages 32-41

  Hameyer, Dorothe ^a   Loonstra, Ate ^b   Eshkind, Leonid ^a   Schmitt, Steffen ^a   Antunes, Cecilia ^a   Groen, Annemiek ^b,d   Bindels, Eric ^b   Jonkers, Jos ^c   Krimpenfort, Paul ^b   Meuwissen, Ralph ^b   Rijswijk, Loes ^b   Bex, Axel ^c   Berns, Anton ^b   Bockamp, Ernesto ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Conditional animal model; Functional genomics; General conditional deleter mouse; In vivo Cre background activity

Indexed keywords

CRE RECOMBINASE; ESTROGEN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CREERT2 GENE; DNA RECOMBINATION; ENZYME ASSAY; ENZYME INDUCTION; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENETIC ANALYSIS; GENOTOXICITY; MOSAICISM; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REPORTER GENE; ROSA26 GENE; SKIN CANCER;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DNA; FLOW CYTOMETRY; GENE DELETION; GENES, REPORTER; GENOMICS; INTEGRASES; LIGANDS; MICE; MICE, TRANSGENIC; MODELS, GENETIC; MOSAICISM; RECOMBINATION, GENETIC;

ANIMALIA; MUS;

EID: 34548817270     PISSN: 10948341     EISSN: 15312267     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00019.2007     Document Type: Article

References (44)

1. Abremski KE, Hoess RH. Evidence for a second conserved arginine residue in the integrase family of recombination proteins. Protein Eng 5: 87-91, 1992.
2. Adams DJ, van der Weyden L. Are we creating problems? Negative effects of Cre recombinase. Genesis 29: 115, 2001.
3. Baba Y, Nakano M, Yamada Y, Saito I, Kanegae Y. Practical range of effective dose for Cre recombinase-expressing recombinant adenovirus without cell toxicity in mammalian cells. Microbiol Immunol 49: 559-570, 2005.
4. Bockamp E, Antunes C, Maringer M, Heck R, Presser K, Beilke S, Ohngemach S, Alt R, Cross M, Sprengel R, Hartwig U, Kaina B, Schmitt S, Eshkind L. Tetracycline-controlled transgenic targeting from the SCL locus directs conditional expression to erythrocytes, megakaryocytes, granulocytes, and c-kit-expressing lineage-negative hematopoietic cells. Blood 108: 1533-1541, 2006.
5. Bockamp E, Maringer M, Spangenberg C, Fees S, Fraser S, Eshkind L, Oesch F, Zabel B. Of mice and models: improved animal models for biomedical research. Physiol Genomics 11: 115-132, 2002.
6. Brake RL, Simmons PJ, Begley CG. Cross-contamination with tamoxifen induces transgene expression in non-exposed inducible transgenic mice. Genet Mol Res 3: 456-462, 2004.
7. Branda CS, Dymecki SM. Talking about a revolution: the impact of site-specific recombinases on genetic analyses in mice. Dev Cell 6: 7-28, 2004.
8. Brocard J, Feil R, Chambon P, Metzger D. A chimeric Cre recombinase inducible by synthetic,but not by natural ligands of the glucocorticoid receptor. Nucleic Acids Res 26: 4086-4090, 1998.
9. Brocard J, Warot X, Wendling O, Messaddeq N, Vonesch JL, Chambon P, Metzger D. Spatio-temporally controlled site-specific somatic mutagenesis in the mouse. Proc Natl Acad Sci USA 94: 14559-14563, 1997.
10. Chang HS, Lin CH, Chen YC, Yu WC. Using siRNA technique to generate transgenic animals with spatiotemporal and conditional gene knockdown. Am J Pathol 165: 1535-1541, 2004.
11. Clarke AR, Maandag ER, van Roon M, van der Lugt NM, van der Valk M, Hooper ML, Berns A, te Riele H. Requirement for a functional Rb-1 gene in murine development. Nature 359: 328-330, 1992.
12. Constien R, Forde A, Liliensiek B, Grone HJ, Nawroth P, Hammerling G, Arnold B. Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 30: 36-44, 2001.
13. Coumoul X, Deng CX. RNAi in mice: a promising approach to decipher gene functions in vivo. Biochimie 88: 637-643, 2006.
14. Danielian PS, Muccino D, Rowitch DH, Michael SK, McMahon AP. Modification of gene activity in mouse embryos in utero by a tamoxifen-inducible form of Cre recombinase. Curr Biol 8: 1323-1326, 1998.
15. de Alboran IM, O'Hagan RC, Gartner F, Malynn B, Davidson L, Rickert R, Rajewsky K, DePinho RA, Alt FW. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity 14: 45-55, 2001.
16. Feil R, Brocard J, Mascrez B, LeMeur M, Metzger D, Chambon P. Ligand-activated site-specific recombination in mice. Proc Natl Acad Sci USA 93: 10887-10890, 1996.
17. Feil R, Wagner J, Metzger D, Chambon P. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem Biophys Res Commun 237: 752-757, 1997.
18. Garcia-Otin AL, Guillou F. Mammalian genome targeting using site-specific recombinases. Front Biosci 11: 1108-1136, 2006.
19. Guo C, Yang W, Lobe CG. A Cre recombinase transgene with mosaic, widespread tamoxifen-inducible action. Genesis 32: 8-18, 2002.
20. Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol 244: 305-318, 2002.
21. Hirsimaki P, Aaltonen A, Mantyla E. Toxicity of antiestrogens. Breast J 8: 92-96, 2002.
22. Indra AK, Warot X, Brocard J, Bornert JM, Xiao JH, Chambon P, Metzger D. Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. Nucleic Acids Res 27: 4324-4327, 1999.
23. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29: 418-425, 2001.
24. Kellendonk C, Tronche F, Monaghan AP, Angrand PO, Stewart F, Schutz G. Regulation of Cre recombinase activity by the synthetic steroid RU 486. Nucleic Acids Res 24: 1404-1411, 1996.
25. Kemp R, Ireland H, Clayton E, Houghton C, Howard L, Winton DJ. Elimination of background recombination: somatic induction of Cre by combined transcriptional regulation and hormone binding affinity. Nucleic Acids Res 32: e92, 2004.
26. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science 269: 1427-1429, 1995.
27. Loonstra A, Vooijs M, Beverloo HB, Allak BA, van Drunen E, Kanaar R, Berns A, Jonkers J. Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. Proc Natl Acad Sci USA 98: 9209-9214, 2001.
28. Metzger D, Clifford J, Chiba H, Chambon P. Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase. Proc Natl Acad Sci USA 92: 6991-6995, 1995.
29. Meuwissen R, Linn SC, van der Valk M, Mooi WJ, Berns A. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene 20: 6551-6558, 2001.
30. Mijimolle N, Velasco J, Dubus P, Guerra C, Weinbaum CA, Casey PJ, Campuzano V, Barbacid M. Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. Cancer Cell 7: 313-324, 2005.
31. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-199, 1991.
32. Pfeifer A, Brandon EP, Kootstra N, Gage FH, Verma IM. Delivery of the Cre recombinase by a self-deleting lentiviral vector: efficient gene targeting in vivo. Proc Natl Acad Sci USA 98: 11450-11455, 2001.
33. Prawitt D, Brixel L, Spangenberg C, Eshkind L, Heck R, Oesch F, Zabel B, Bockamp E. RNAi knock-down mice: an emerging technology for post-genomic functional genetics. Cytogenet Genome Res 105: 412-421, 2004.
34. Schmidt EE, Taylor DS, Prigge JR, Barnett S, Capecchi MR. Illegitimate Cre-dependent chromosome rearrangements in transgenic mouse spermatids. Proc Natl Acad Sci USA 97: 13702-13707, 2000.
35. Schwenk F, Kuhn R, Angrand PO, Rajewsky K, Stewart AF. Temporally and spatially regulated somatic mutagenesis in mice. Nucleic Acids Res 26: 1427-1432, 1998.
36. Seibler J, Zevnik B, Kuter-Luks B, Andreas S, Kern H, Hennek T, Rode A, Heimann C, Faust N, Kauselmann G, Schoor M, Jaenisch R, Rajewsky K, Kuhn R, Schwenk F. Rapid generation of inducible mouse mutants. Nucleic Acids Res 31: e12, 2003.
37. Silver DP, Livingston DM. Self-excising retroviral vectors encoding the Cre recombinase overcome Cre-mediated cellular toxicity. Mol Cell 8: 233-243, 2001.
38. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 21: 70-71, 1999.
39. van der Weyden L, Adams DJ, Bradley A. Tools for targeted manipulation of the mouse genome. Physiol Genomics 11: 133-164, 2002.
40. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Van Parijs L, Jaenisch R, Jacks T. Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci USA 101: 10380-10385, 2004.
41. Vitale-Cross L, Amornphimoltham P, Fisher G, Molinolo AA, Gutkind JS. Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis. Cancer Res 64: 8804-8807, 2004.
42. Vooijs M, Jonkers J, Berns A. A highly efficient ligand-regulated Cre recombinase mouse line shows that LoxP recombination is position dependent. EMBO Rep 2: 292-297, 2001.
43. Wunderlich FT, Wildner H, Rajewsky K, Edenhofer F. New variants of inducible Cre recombinase: a novel mutant of Cre-PR fusion protein exhibits enhanced sensitivity and an expanded range of inducibility. Nucleic Acids Res 29: E47, 2001.
44. Zhang Y, Riesterer C, Ayrall AM, Sablitzky F, Littlewood TD, Reth M. Inducible site-directed recombination in mouse embryonic stem cells. Nucleic Acids Res 24: 543-548, 1996.